Jasper Therapeutics, Inc.JSPRNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank39
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P39
Within normal range
vs 2Y Ago
-1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q3 2025-10.00%
Q2 202532.35%
Q1 2025-8.08%
Q4 2024-50.40%
Q3 2024-20.31%
Q2 202425.78%
Q1 20244.51%
Q4 2023-37.54%
Q3 20239.73%
Q2 2023-28.42%
Q1 202318.27%
Q4 2022-31.14%
Q3 2022-3.07%
Q2 202234.17%
Q1 20222.54%
Q4 202120.81%
Q3 2021-218.00%
Q2 20216.52%
Q1 2021-14.87%
Q4 2020-67933.30%
Q3 2020-128.44%
Q2 202098.51%
Q1 20200.00%
Q4 20190.00%